Temozolomide Not Effective for Brain Metastases from Breast Cancer
the Cancer Therapy Advisor take:
According to a new study published in the journal Annals of Oncology, whole-brain radiotherapy plus temozolomide does not improve local control, progression-free survival, or overall survival in patients with brain metastases from breast cancer.
For the multicenter, prospective, phase 2 study, researchers sought to investigate the safety and efficacy of whole-brain radiation therapy plus temozolomide for the treatment of patients with brain metastases from breast cancer.
They enrolled 100 patients with newly diagnosed intraparenchymal brain metastases from breast cancer who were not candidates for surgery or radiosurgery. Participants were randomly assigned to receive whole-brain radiation therapy with or without temozolomide. Patients were followed for a median of 9.4 months.
At 6 weeks, patients in combination arm achieved an objective response rate of 30% compared with 36% in the whole-brain radiation therapy alone group. Median progression-free survival for the combination group and radiation alone group were 6.9 months and 7.4 months, respectively. Median overall survival for those receiving radiation therapy plus temozolomide was 9.4 months versus 11.1 months among those receiving radiation alone.
Both treatments were well tolerated. The findings suggest that the addition of temozolomide to whole-brain radiation therapy for the treatment of brain metastases from breast cancer is not more effective that whole-brain radiation therapy alone.
Radiotherapy + temozolomide does not improve survival in patients with brain metastases from breast cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- High IDO1 Tumor Expression May Predict Poor Overall Survival in Patients With Anal Cancer
- Ambient Benzene Exposure and Risk of Hematologic Malignancies
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma